先看重点
四个美国专业学会的联合专家建议指出,GLP-1类药物在试验中可使体重下降5%至18%,真实世界中效果略低,需要营养和生活方式干预来应对副作用、肌肉和骨量流失及体重反弹。这是基于文献评估的专家共识,不是试验,其优先事项属于建议而非检验过的结果。
证据类型
研究论文
解读依据
公开摘要
阅读重点
方法与适用范围
研究在问什么
GLP-1受体激动剂及相关复方药物正在改变肥胖治疗,但副作用、营养缺乏、肌肉流失、长期依从性差和费用高都会削弱获益。作者代表四个美国专业学会,想为治疗这类患者的临床医生提出实用的营养与生活方式优先事项。
研究了谁,如何研究
由多学科临床和研究专家组成的小组,由美国生活方式医学会、美国营养学会、肥胖医学协会和肥胖学会共同发起。专家结合自身知识和临床经验评估科学文献,归纳相关主题、优先事项和新方向。摘要未说明是否做过系统检索,也未对证据质量评分。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1GLP-1类药物在试验中使体重下降5%至18%,真实世界分析中效果略低,并带来多方面已证实的临床获益。
- 2主要问题包括胃肠道副作用、因摄入减少导致的营养缺乏、肌肉和骨量流失、长期依从性低伴体重反弹,以及费用高昂。
- 3多项指南已推荐成人肥胖采用多成分营养与行为治疗,但与GLP-1联合使用并不普遍。
- 4优先事项包括用药前筛查(饮食习惯、情绪诱因、进食障碍、肌力与身体成分、社会需求、活动、睡眠和压力)、处理副作用、预防营养缺乏,以及通过抗阻训练和合理饮食保护肌肉和骨量。
- 5支持方式包括团体门诊、注册营养师咨询、远程医疗和数字平台以及“食物即医学”项目;停药后如何维持体重仍有待研究。
局限与不确定性
- 1这是专家建议,优先事项反映作者对文献的判断,而不是系统综述或新数据。
- 2摘要没有说明各条建议的证据强度,且部分内容被列为仍需研究的方向。
- 3减重幅度来自试验,个人的实际效果可能不同。
对日常健康的启示
如果你正在使用或考虑使用GLP-1药物,可以向医生询问蛋白质与整体饮食、抗阻训练以及营养缺乏筛查,而不是只依赖药物。是否开始、调整或停用药物,应由你与医生决定。
如何联系自己的数据
用药期间值得记录体重趋势、饮食、力量训练次数、每日步数和睡眠时长。体重应在每天同一时间、用同一台秤测量,并看数周的趋势;单看体重无法反映肌肉流失,可与医疗团队讨论身体成分检查。
如何理解这类证据
索引未明确确定具体研究设计,应先读方法;核对人群、对照、结局和不确定性,再判断能否作因果解释。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.
Objectives
We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.
Methods
An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.
Results
GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.
Conclusions
Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP-1 treatment of obesity, making clinicians more effective in advancing their patients' health.
来源与署名
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA.
Obesity (Silver Spring, Md.) · 2025-05-30
DOI: 10.1002/oby.24336 ↗PubMed · 40445127 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
更早的进食窗口与更大的体重和胰岛素获益相关,优于晚间进食
汇总41项随机对照试验(2287名参与者,干预时间中位数8周)发现,限时进食比日常饮食体重低2.15 kg(95%置信区间−2.56至−1.74),而早吃比晚吃体重多降1.15 kg(95%置信区间−1.86至−0.45)。多数试验较短,只有6个研究组检验了早间进食,结局是身体和血液指标,不是心脏病发作或死亡。
BMJ Medicine
限热量饮食再加上午8点至下午4点进食窗口,1年减重无明显额外优势
139名肥胖患者都按限制热量的饮食进食,其中一组再加上上午8:00至下午4:00的进食窗口,12个月平均体重变化为−8.0 kg,单纯限热量组为−6.3 kg。净差值−1.8 kg(95%置信区间−4.0至0.4;P=0.11)无统计学意义,该区间既不能排除窗口确有获益,也不能排除毫无作用。
The New England Journal of Medicine
20人住院试验:超加工饮食让人每天多摄入508 kcal并增重
20名成年人在医院研究病房住了28天,两种菜单各吃2周、想吃多少吃多少:超加工菜单让他们每天多摄入508 kcal(±106,标准误,P=0.0001),体重增加0.9 kg;未加工菜单则让体重减轻0.9 kg。样本小、周期短、食物全程由研究方提供,既不能说明日常生活中的长期结果,也无法确定是食物的哪种特点导致多吃。
Cell Metabolism
地中海饮食加橄榄油或坚果与心血管事件减少相关(更正后的试验)
在7447名55至80岁、心血管风险较高的西班牙成年人中,被分到加特级初榨橄榄油(风险比0.69,95%置信区间0.53至0.91)或加坚果(风险比0.72,0.54至0.95)的地中海饮食组,发生主要心血管事件的风险低于被告知减少脂肪的对照组。试验存在随机化失误,2013年的报告已撤回并重新估算,证据有力但并不完美。
The New England Journal of Medicine

